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Abstract
Background: Governmental debate in Ireland on the de facto decriminalisation of cannabis and legalisation for
medical use is ongoing. A cannabis-based medicinal product (Sativex®) has recently been granted market
authorisation in Ireland. This unique study aimed to investigate Irish general practitioner (GP) attitudes toward
decriminalisation of cannabis and assess levels of support for use of cannabis for therapeutic purposes (CTP).
Methods: General practitioners in the Irish College of General Practitioner (ICGP) database were invited to complete
an online survey. Anonymous data yielded descriptive statistics (frequencies, percentages) to summarise participant
demographic information and agreement with attitudinal statements. Chi-square tests and multi-nominal logistic
regression were included.
Results: The response rate was 15% (n = 565) which is similar to other Irish national GP attitudinal surveys. Over half
of Irish GPs did not support the decriminalisation of cannabis (56.8%). In terms of gender, a significantly higher
proportion of males compared with females (40.6 vs. 15%; p < 0.0001) agreed or strongly agreed with this drug
policy approach. A higher percentage of GPs with advanced addiction specialist training (level 2) agreed/strongly
agreed that cannabis should be decriminalised (54.1 vs. 31.5%; p = 0.021). Over 80% of both genders supported the
view that cannabis use has a significant effect on patients’ mental health and increases the risk of schizophrenia
(77.3%). Over half of Irish GPs supported the legalisation of cannabis for medical use (58.6%). A higher percentage
of those who were level 1-trained (trained in addiction treatment but not to an advanced level) agreed/strongly
agreed cannabis should be legalised for medical use (p = 0.003). Over 60% agreed that cannabis can have a role in
palliative care, pain management and treatment of multiple sclerosis (MS). In the regression response predicator
analysis, females were 66.2% less likely to agree that cannabis should be decriminalised, 42.5% less likely to agree
that cannabis should be legalised for medical use and 59.8 and 37.6% less likely to agree that cannabis has a role in
palliative care and in the treatment of multiple sclerosis (respectively) than males.
Conclusions: The majority of Irish GPs do not support the present Irish governmental drug policy of
decriminalisation of cannabis but do support the legalisation of cannabis for therapeutic purposes. Male GPs and
those with higher levels of addiction training are more likely to support a more liberal drug policy approach to
cannabis for personal use. A clear majority of GPs expressed significant concerns regarding both the mental and
physical health risks of cannabis use. Ongoing research into the health and other effects of drug policy changes on
cannabis use is required.
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Background
Cannabis is the most prevalent illicit drug used globally
[1]. The policy landscape around cannabis is dynamic [2],
with three drug policy options available, prohibition, de-
criminalisation and legalisation [3]. In recent years, the
legal status of cannabis has been extensively debated in
academic and policy domains, with many jurisdictions
making or considering major changes in their domestic
laws and policies on this issue. The International Centre
for Science in Drug Policy have advised that such policy
responses need to be based on best available evidence [4].
The United Nations (UN) Drug Conventions support
the prohibitionist approach and require signatories to
make the possession of cannabis a criminal offence
under their domestic laws [5]. Policy makers challenging
this approach argue that the criminalisation of cannabis
is an expensive and ineffective drug control policy which
has no impact on reducing availability or use despite its
significant financial costs [6]. Proponents for policy
change support a less punitive approach to cannabis
users with a greater emphasis on public health and hu-
man rights [2, 5, 6]. The decriminalisation drug policy
approach involves the removal of criminal sanctions for
those found in possession of small amounts of the drug
for their own use [5]. However, the use of the drug is not
legal, and non-criminal offences may still be applied [5].
Underpinning this approach is the argument that cannabis
is a relatively safe drug when compared to alcohol and to-
bacco, and criminal sanctions for personal use and posses-
sion of small amounts are excessive [6]. Prohibitionist
continues to argue that removal of criminal barriers will
lead to increased supply, use, dependence and harm [3].
With increasing public support for the decriminalisa-
tion of cannabis use, some jurisdictions are now devel-
oping and implementing a range of legally regulated
market models for recreational cannabis use [2]. Legal-
isation of cannabis usually refers to the removal of all
criminal and non-criminal sanctions for its use, produc-
tion and supply. However, legal regulation will set out the
rules and restrictions around how these can occur [5].
Despite widespread prohibition, many multiple scler-
osis and chronic pain patients use cannabis for analgesia
and psychological support [7]. Some states in the USA
have moved toward allowing individuals to use cannabis
for medical purposes [5], with resultant debate on
whether these laws have led to increased use [8]. De-
bates around legalisation of medical cannabis centre on
the beliefs that cannabis has medical effects, medical
cannabis is addictive and that legalisation leads to in-
creased use for recreation (i.e. spillover effects) [9]. Some
reports indicate the potential value of cannabis for thera-
peutic purposes (CTP) [10–15]. However, some concerns
around the addictive potential of cannabis are evident
[4, 5, 16] but with a weak evidence base indicating
lower probability of dependence and physical and social
harm when compared to alcohol, cocaine, opiates and
nicotine [4]. Legalisation in the form of de facto legal sup-
ply for medical use (CTP) does not appear to have created
a significant threat to public health and safety, or caused
increased consumption or related harms [17–20]. In terms
of patient experience, legalisation appears to increase pa-
tient’s feelings of safety and awareness [21].
To date, eight US states (Alaska, California, Colorado,
Oregon, Massachusetts, Maine, Nevada and Washington)
have now voted to legalise cannabis for both medical and
non-medical use, and one state (Washington DC) has
legalised it for personal use but not commercial sale [5].
Regulatory debates are ongoing in many countries includ-
ing Canada, Jamaica, Italy, Spain, several Latin American
countries and additional US states [5].
To date, research on medical practitioner views on this
issue remains scant [17]. In the past 20 years, only a
minority of oncologists surveyed in the USA were in sup-
port of the rescheduling of cannabis for medical purposes
[22] and the availability of cannabis on prescription [23].
More recently, in the USA, medical practitioner views on
medical cannabis are generally less supportive of medical
use, underpinned by recognition of its potential for serious
mental and physical health risks [24, 25]. Israeli practi-
tioners have voiced partial acceptance for therapeutic use,
with further research warranted to investigate educational
and regulatory needs [26]. Israeli rheumatologists in 2016
report majority opinion of some role for cannabinoids in
the management of rheumatoid disease [27].
Our study is the first of its kind in Ireland and aimed
to investigate Irish general practitioner (GP) attitudes to-
ward decriminalisation of cannabis and assess levels of
support for CTP. The study was undertaken on foot of
several regulatory developments and debates in Ireland,
in particular, a recent governmental debate and report-
ing from the Oireachtas Justice Committee on the pro-
posed decriminalisation of cannabis. The committee
recommended that possession of small amounts of can-
nabis for personal use should not be dealt with through
the criminal justice system and that small-scale users
should be treated with compassion. Other debates
centred on CTP in Ireland with authorisation necessary
from the Health Products Regulatory Authority (HPRA)
or, in the case of certain medicinal products, the European
Medicines Agency (EMA). In July 2014, regulations were
amended to allow for certain cannabis-based medicinal
products to be used in Ireland. The HPRA granted a mar-
keting authorisation for a cannabis-based medicinal prod-
uct (Sativex®) which is indicated for the treatment of
spasticity for people with multiple sclerosis. However, the
most recent national treatment data indicates cannabis is
the most common problem drug among new cases pre-
senting for drug treatment [28].
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Methods
In Ireland, medical training for general practitioners is
overseen by the Irish College of General Practitioners
(ICGP). Training in substance misuse is provided as
levels 1 and 2 training. GPs trained to these levels have
acquired additional knowledge and experience in the
treatment and management of substance use problems.
Ethical approval was granted by the ICGP. In early 2016,
an online survey was undertaken with all GPs in the
ICGP database based in the Republic of Ireland. Elec-
tronic invitations included information on the study and
consent information, and a link to access the online sur-
vey was sent. A notice encouraging response was also
placed on the substance misuse section of the ICGP
website. The survey was designed based on a review of
the literature and in consultation with the project team.
The instrument contained a series of closed questions
relating to participant profile and practice location, spe-
cialist registration, experience in treating opioid users
and their responses toward a five-point Likert scale
measuring agreement with a series of statements. State-
ments measured attitude toward decriminalisation of
cannabis, legalisation for CTP, potential for decriminal-
isation to increase cannabis use, adverse mental and
physical health effects of cannabis use, cannabis use in
young people and risk of development of schizophrenia
and role of CTP in pain management, treatment of mul-
tiple sclerosis and palliative care. The survey took an es-
timated 10 min to complete. While the response rate for
this online survey was low (15%), it is consistent with
the response rates from GPs nationally and internation-
ally for similar type of studies [29–31].
Anonymous data yielded descriptive statistics (frequen-
cies, percentages) to summarise participant demographic
information and agreement with attitudinal statements.
Statistical analysis was performed using the Statistical
Package for Social Sciences (Version 21.0; SPSS UK Ltd;
Chersey, UK). Where appropriate, chi-square tests were
applied to determine the statistical significance (p < 0.05).
Multi-nominal logistic regression analysis was used to de-
termine predictors of answer responses with the neutral
response category as the reference.
Results
Participant characteristics
The participant characteristics are displayed in Table 1.
There was no significant difference in the proportion of
males or females sampled (p = 0.180). The majority of
males (50.5%) tended to be older (>50 years), while the
majority of females were aged between 30–50 years
(62.4%). Most of the participants were full-time practi-
tioners, (71.3%) though significantly more males were re-
tired compared with females (8.6 vs. 4.2%; p = 0.030),
while significantly more females were trainees (23.0 vs.
15.1%; p = 0.017). Over 70% of respondents were on the
GP Specialist Register of the Irish Medical Council with
85% working in general practice. Nearly 30% of the sample
was level 1-trained managing opioid users, while only
4.4% were level 2-trained. There was no difference across
gender in the practice population with the majority work-
ing in an urban area (43.7%) with nearly 40% working in
an area of deprivation. Selection bias is limited as all
demographics of the responding group are consistent with
the national data on GPs [32, 33] (Table 1).
Statement responses
The answer responses were examined by gender, age and
training level. A significantly higher proportion of males
compared with females (40.6 vs. 15.0%; p < 0.0001) agreed
or strongly agreed that cannabis should be decriminalised,
while more males than females also agreed that cannabis
should be legalised for medical use (p = 0.002). There were
no significant differences in the responses to the remaining
questions by gender; for example, approximately 80% of
both genders agreed that cannabis use has a significant ef-
fect on patients’ mental health and increases the risk of
schizophrenia (77.3%), while over 60% of both males and
females agreed that cannabis can have a role in pain man-
agement, multiple sclerosis and palliative care (Table 2).
When analysed by age, only 29% of those aged <50 years
agreed that cannabis should be decriminalised. In contrast,
a significantly higher proportion of those aged >50 years
agreed that cannabis should be legalised for medical use
compared to the younger GPs sampled (71.1 vs.
79.6%; p = 0.044). When analysed by level of training,
a higher percentage of those who were level 1-trained
agreed/strongly agreed cannabis should be legalised for
medical use (p = 0.003). However, a significantly lower
proportion of this group agreed/strongly agreed that can-
nabis has a role in pain management (p = 0.032), in treat-
ment of multiple sclerosis (p = 0.037) and in palliative care
(p = 0.047) compared to those who are not level 1-trained.
In contrast, a higher percentage of those level 2-trained
agreed/strongly agreed that cannabis should be decrimina-
lised compared to those without this training (54.1 vs.
31.5%; p = 0.021) (Tables 3, 4 and 5).
In the regression response predicator analysis, females
were 66.2% less likely to agree that cannabis should be
decriminalised, and 42.5% less likely to agree that canna-
bis should be legalised for medical use compared with
males. Females were also 59.8 and 37.6% less likely to
agree that cannabis has a role in palliative care and a
role in the treatment of multiple sclerosis (respectively)
than males. Furthermore, GPs based in a non-deprived
area were 56.4% more likely to agree that cannabis has a
role in pain management compared to those working in
a deprived area, while GPs aged 30–50 years were
189.5% more likely to disagree that cannabis can have a
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role in the treatment of multiple sclerosis compared to
those not in that age group (Table 6).
Discussion
This study yielded unique findings with regard to Irish
GP views on decriminalisation of cannabis and the med-
ical use of cannabis (CTP). The majority of GPs did not
support the decriminalisation of cannabis, but male re-
spondents were significantly more likely to support this
drug policy approach than their female counterparts.
This majority view is contrary to current Irish
government policy on the issue. Nearly 60% of GPs sup-
ported the legalisation of cannabis for medical use with
older (>50) and male GPs more likely to favour this ap-
proach. In contrast to the view on decriminalisation, this
majority view supports Irish government policy on CTP.
In 2000, the Irish Drug Related Knowledge, Attitudes
and Beliefs survey found that males reported greater use
of cannabis and knowledge of cannabis users than fe-
males [34]. This study, while dated, indicated that only
24% were in favour of legalisation of cannabis. Of inter-
est is that the majority of GPs trained to a more
Table 2 Statement responses by gender
Total n (%) Agreed
Female Male p value
Cannabis should be decriminalised 156 (27.6) 43 (15.0) 113 (40.6) <0.0001
Cannabis should be legalised for medical use 331 (58.6) 146 (50.9) 185 (66.5) 0.002
The decriminalisation of cannabis use would lead to its increased use 373 (66.0) 200 (69.7) 173 (62.2) 0.089
Cannabis use has a significant adverse effect on patients’ mental health 467 (82.7) 246 (85.7) 221 (79.5) 0.346
Cannabis use has a significant adverse effect on patients’ physical health 339 (60.0) 175 (61.0) 164 (59.0) 0.111
Cannabis use among young people increases the risk of schizophrenia 437 (77.3) 228 (79.4) 209 (75.2) 0.990
Cannabis has a role to play in pain management 359 (63.5) 166 (57.8) 193 (69.4) 0.511
Cannabis can have a role in the treatment of multiple sclerosis 352 (62.3) 165 (57.5) 187 (67.3) 0.914
Cannabis can have a role in palliative care 387 (68.5) 175 (61.0) 212 (76.3) 0.362
Total agreed (strongly agree and agree). Values are n (%); chi-square analysis for categorical variables for comparisons of distributions between gender
Table 1 Participant characteristics
Total (n 565) Male (n 278) Female (n 287) p value
Age n (%)
<30 years 41 (7.3) 16 (5.8) 25 (8.7) 0.180
30–50 years 300 (53.2) 121 (43.7) 179 (62.4) 0.288
>50 years 223 (39.5) 140 (50.5) 83 (28.9) <0.0001
Membership of the ICGP n (%)
Associate, part-time, others 18 (3.2) 8 (2.9) 10 (3.5) 0.681
Full-time 403 (71.3) 204 (73.4) 199 (69.3) 0.288
Retired 36 (6.4) 24 (8.6) 12 (4.2) 0.030
Trainee 108 (19.1) 42 (15.1) 66 (23.0) 0.017
Training n (%)
On the GP specialist register 435 (77.5) 216 (78.3) 219 (76.8) 0.687
Working in general practice 482 (85.3) 242 (87.1) 240 (83.6) 0.250
Working in academic general practice 129 (23.0) 64 (23.4) 65 (22.7) 0.859
Level 1-trained GP managing opioid users 169 (29.9) 77 (27.7) 92 (32.1) 0.258
Level 2-trained GP managing opioid users 25 (4.4) 16 (5.8) 9 (3.1) 0.130
Practice population n (%)
Mixed 211 (39.7) 110 (41.5) 101 (38.0) 0.405
Rural 88 (16.6) 42 (15.8) 46 (17.3) 0.655
Urban 232 (43.7) 113 (42.6) 119 (44.7) 0.626
Working in an area of deprivation 211 (39.4) 99 (37.4) 112 (41.5) 0.329
Values are n (%); chi-square analysis for categorical variables for comparisons of distributions between gender
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specialist level in addictions supported decriminalisation
(54.1% p = 0.021). This may in part be due to their ex-
perience treating patients with opioid dependence in
particular injecting drug users. In this patient cohort,
cannabis use is often considered a secondary issue when
managing the high-risk behaviour and health issues asso-
ciated with injecting drug use. In contrast, in terms of
gender, regression analyses revealed that females were
less likely to agree that cannabis should be decrimina-
lised. Prevalence data in Ireland has reported little
change in women’s rates of cannabis use, with preva-
lence rates highest among men and younger adults aged
15–34 years [35]. Research shows that individuals with
personal experience of cannabis use are more inclined to
be in favour of legalising [36]. According to the National
Advisory Committee on Drugs and Alcohol (NACDA)
in 2012 general population survey, the majority of re-
spondents agreed with medical use of cannabis and dis-
agreed with recreational use of cannabis. This is
consistent with the drug policy approaches supported by
Irish GPs in this survey.
Both genders of GPs in this study voiced concerns that
decriminalisation would lead to increased use and the
misuse of prescribed versions if available. Hall and
Lynskey [37] speculate that potential effects of legalising
recreational cannabis use, while substantially reducing
the price, increasing excessive use and related harms,
may also increase the number of new users. However, of
interest, is recent reporting of a great overlap between
medicinal and recreational cannabis use in the USA [38].
Regulating the cannabis market via prohibition and de-
criminalisation has a marginal effect on onset of canna-
bis use and population consumption rates [6]. Yuyan et
al. [39] in their review of 38 countries indicated that
cannabis liberalisation with depenalization and partial
prohibition policies was associated with higher levels of
regular cannabis use among adolescents. This is con-
cerning given a recent Irish study [40] which under-
scored the relatively low levels of adolescent-perceived
risk of mental and physical health problems with use of
the drug. According to Eurobarometer [41], Ireland has
the highest number of young people who have used
Table 3 Statement responses by age
n (%) Agreed
<50 years >50 years p value
Cannabis should be decriminalised 85 (29.7) 71 (37.3) 0.082
Cannabis should be legalised for medical use 190 (71.1) 141 (79.6) 0.044
The decriminalisation of cannabis use would lead to its increased use 232 (82.2) 141 (82.4) 0.960
Cannabis use has a significant adverse effect on patients’ mental health 281 (92.4) 185 (92.5) 0.978
Cannabis use has a significant adverse effect on patients’ physical health 210 (81.3) 128 (81.5) 0.973
Cannabis use among young people increases the risk of schizophrenia 269 (91.8) 167 (89.3) 0.354
Cannabis has a role to play in pain management 221 (88.4) 138 (82.1) 0.072
Cannabis can have a role in the treatment of multiple sclerosis 208 (92.4) 144 (87.8) 0.123
Cannabis can have a role in palliative care 235 (90.0) 152 (85.3) 0.139
Total agreed (strongly agree and agree). Values are n (%); chi-square analysis for categorical variables for comparisons of distributions between age
Table 4 Statement responses by training level (level 1)
n (%) Agreed
Not level 1 Level 1 p value
Cannabis should be decriminalised 114 (34.7) 42 (28.1) 0.156
Cannabis should be legalised for medical use 245 (78.5) 86 (65.1) 0.003
The decriminalisation of cannabis use would lead to its increased use 264 (83.0) 109 (80.1) 0.464
Cannabis use has a significant adverse effect on patients’ mental health 321 (92.2) 146 (92.9) 0.767
Cannabis use has a significant adverse effect on patients’ physical health 229 (80.3) 110 (83.9) 0.377
Cannabis use among young people increases the risk of schizophrenia 301 (89.5) 136 (93.7) 0.142
Cannabis has a role to play in pain management 262 (88.2) 97 (80.1) 0.032
Cannabis can have a role in the treatment of multiple sclerosis 257 (92.4) 95 (85.5) 0.037
Cannabis can have a role in palliative care 282 (90.0) 105 (83.3) 0.047
Total agreed (strongly agree and agree).Values are n (%); chi-square analysis for categorical variables for comparisons of distributions between level 1 training
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cannabis in the past year (28%), compared to a Europian
Union (EU) average of 17%; 58% of Irish youth have
never taken cannabis, which in 2014 is third lowest in
Europe and well below the EU average of 69%. Overall,
46% of young Irish people consider regular cannabis use
to be high risk, compared to an EU average of 63%. The
Eurobarometer in 2014 [41] also reported that 56% of
Irish 15–24-year-olds were of the view that the cannabis
market should be regulated, which is almost a reverse
position of the EU average, where 45% said cannabis
should be regulated, and 53% said it should continue to
be banned.
GPs in this national study agreed that cannabis use
has a significant effect on patients’ mental health and in-
creases the risk of schizophrenia. Kondrad and Reid [25]
have reported majority agreement of US physicians in
Colorado regarding the serious mental and physical
health risks of cannabis. Irish GPs in this study under-
scored their experience of the significant adverse effect
on patient mental health and risks of schizophrenia in
young users. Heavy use of cannabis at an earlier age is
reported to heighten risk of dependence, depressive
disorders, psychosis, suicidal ideation, development of
schizophrenia and related negative social consequences
[17]. This contributes to the debate around the canna-
binoid hypothesis of psychosis, for example that expos-
ure to cannabis and cannabinoid agonists is associated
with psychosis outcomes through activation of CB1R
[42–44]. However, to date, a causal relationship has not
been established [4].
Kondrad and Reid [25] in their 2013 study of physician
experiences and attitudes to medical cannabis reported
that nearly half of participants did not support CTP and
that only a minority thought therapeutic use of cannabis
conferred physical and mental health benefits. Israeli
practitioners in 2015 voiced partial acceptance for thera-
peutic use, and generally agreed that CTP could be helpful
for chronic and for terminally ill patients [26]. However,
oncologists and pain specialists did not agree unanimously
that medical cannabis can undermine mental health,
whereas other physicians did [26]. CTP is driven by public
approval without scientific data routinely required to jus-
tify new medication regulation [45, 46]. In 2005, US physi-
cians reported less support of CTP than the public [24].
Irish GPs who reported practicing in a non-deprived area
in this study were more likely to agree that cannabis has a
Table 5 Statement responses by training level (level 2)
n (%) Agreed
Not level 2 Level 2 p value
Cannabis should be decriminalised 143 (31.5) 13 (54.1) 0.021
Cannabis should be legalised for medical use 313 (74.1) 18 (81.8) 0.422
The decriminalisation of cannabis use would lead to its increased use 360 (82.7) 13 (68.4) 0.110
Cannabis use has a significant adverse effect on patients’ mental health 446 (92.7) 21 (87.5) 0.344
Cannabis use has a significant adverse effect on patients’ physical health 323 (81.7) 16 (76.1) 0.521
Cannabis use among young people increases the risk of schizophrenia 416 (90.6) 21 (95.4) 0.443
Cannabis has a role to play in pain management 341 (85.6) 18 (90.0) 0.588
Cannabis can have a role in the treatment of multiple sclerosis 337 (90.3) 15 (93.7) 0.650
Cannabis can have a role in palliative care 369 (88.2) 18 (85.7) 0.723
Total agreed (strongly agree and agree). Values are n (%); Chi-square analysis for categorical variables for comparisons of distributions between level 2 training
Table 6 Statement response predicators
Category Variable Beta Exp (B) p value 95% CI
lower upper
Cannabis should be decriminalised Agree Female −1.084 0.338 <0.0001 0.19 0.602
Cannabis should be legalised for medical use Agree Female −0.553 0.575 0.017 0.365 0.907
Cannabis has a role to play in pain management Agree Female −0.644 0.525 0.003 0.343 0.805
Agree Non-deprived area 0.447 1.564 0.041 1.018 2.403
Disagree Not level 1 −0.706 0.494 0.049 0.244 0.998
Cannabis can have a role in the treatment of
multiple sclerosis
Agree Female −0.472 0.624 0.019 0.42 0.926
Disagree Aged 30–50 years 1.063 2.895 0.013 1.257 6.668
Cannabis can have a role in palliative care Agree Female −0.91 0.402 <0.0001 0.255 0.636
Multi-nominal logistic regression analysis; reference category is neutral response
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role in pain management compared to those who reported
working in a deprived area. Level of training for this Irish
sample reflected that a greater percentage of those partici-
pants with level 1 substance misuse training agreed/
strongly agreed that cannabis should be legalised for med-
ical use. While the clear majority of this group supported
the role of medical cannabis in pain management, treat-
ment of multiple sclerosis and palliative care, they were
statistically less supportive than those without this train-
ing. Irish GPs aged 30–50 years were more likely to dis-
agree that cannabis can have a role in the treatment of
multiple sclerosis compared to those not in that age
group. Kondrad and Reid [25] found that age was signifi-
cantly associated with the recommendation of medical
cannabis. They also found no significant association with
physician gender, years in practice, or type of licence and
recommendation of medical cannabis. In contrast, this
study found that female GPs in Ireland were less likely to
agree that cannabis should be legalised for medical use
compared with males, and were also less likely to agree
that cannabis has a role in palliative care or a role in the
treatment of multiple sclerosis than males.
Conclusions
The study is unique in terms of describing Irish GP views
on different drug policy approaches to cannabis use and is
only one of a handful of studies worldwide that examines
physicians’ views on this topical issue. The majority of
Irish GPs do not support decriminalisation of cannabis
use which is now the policy choice of the Irish govern-
ment. This study found interesting differences in views be-
tween male and female GPs and those with different levels
of addiction training and experience. Female GPs tended
to favour a more conservative drug policy approach, while
those with more advanced training supported a more lib-
eral one. The finding of majority support for CTP among
Irish GPs in this study underpins and supports the pro-
posed legislative changes that are presently being consid-
ered by the Irish parliament. While supporting this policy
initiative, a clear majority of GPs viewed that such an ap-
proach had the potential to increase cannabis use and
expressed concerns regarding both the mental and phys-
ical health risks associated with its use. This study cap-
tures the views of Irish GPs on potential policy changes
regarding both medical and recreational cannabis use at a
time when both are prohibited and will facilitate further
research on how these views may change over time
and be influenced by a different policy approach. Fur-
ther research is warranted to explore how gender and
levels of addiction training and experience impact
doctors’ views on drug policy.
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